Abstract
Background Patients infected with SARS-CoV-2 exhibit a highly variable clinical course, varying from barely discernible signs of disease, to moderate flu-like symptoms and, occasionally, with life-threatening pneumonia and/or cytokine storm. The relationship between the nasopharyngeal virus load, IgA and IgG antibodies to both the S1-RBD-protein and the N-protein as well the neutralizing activity (NAbs) against SARS-CoV-2 in the blood of moderately afflicted COVID-19 patients has not been investigated longitudinally so far.
Methods Several new serological methods to examine these parameters were developed and validated for the longitudinal investigation in three patients of a family which underwent a mild course of COVID-19.
Findings We observed that the virus load had almost completely disappeared after about four weeks, whereas serum antibodies showed a contrasting course. IgA levels to S1-RBD-protein and, to a lesser extent, to the N-protein, peaked about three weeks after clinical disease onset but declined soon thereafter. IgG levels rose continuously, reaching a plateau approximately six weeks after disease onset. NAbs in serum reached a peak about four weeks after disease onset but dropped to a lower level about six weeks later.
Interpretation Our data establishes associations of virus neutralization and a serological immune response foremost against Sars-CoV-2 S1-RDB-protein in a longitudinal manner.
Competing Interest Statement
Bertram Flehmig, Angelika Haage, Andrea Normann and Lutz Pridzun are Employees of Mediagnost GmbH Manfred Bayer and Despina Tougianidou are Employees of 4base lab AG
Funding Statement
Michael Schindler and Ramona Businger received basic institutional funds from the University Hospital, Tuebingen. Furthermore Michael Schindler,Natalia Ruetalo and Ramona Businger are being supported by grants from the Baden-Wuerttemberg Foundation and the Deutsche Forschungsgemeinschaft (DFG). Karin Klingel received basic funding by Deutsche Herzstiftung.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Experiments conformed to the Declaration of Helsinki Principles. Written informed consents were obtained from all blood donors prior to the study. The study was approved by the Independent Research Ethics Committee (IEC) of the University of Tuebingen, IEC-Project Number 672/2020A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred in the manuscript are available.